284 related articles for article (PubMed ID: 26252081)
21. Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation.
Huang Y; Liao D; Pan L; Ye R; Li X; Wang S; Ye C; Chen L
Eur J Endocrinol; 2013 May; 168(5):675-81. PubMed ID: 23416953
[TBL] [Abstract][Full Text] [Related]
22. Differential expression profiling and functional analysis of microRNAs through stage I-III papillary thyroid carcinoma.
Zhang J; Liu Y; Liu Z; Wang XM; Yin DT; Zheng LL; Zhang DY; Lu XB
Int J Med Sci; 2013; 10(5):585-92. PubMed ID: 23533107
[TBL] [Abstract][Full Text] [Related]
23. Differential expression profiling of circulation microRNAs in PTC patients with non-131I and 131I-avid lungs metastases: a pilot study.
Qiu ZL; Shen CT; Song HJ; Wei WJ; Luo QY
Nucl Med Biol; 2015 May; 42(5):499-504. PubMed ID: 25682061
[TBL] [Abstract][Full Text] [Related]
24. Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of lung cancer.
Zhang Y; Sui J; Shen X; Li C; Yao W; Hong W; Peng H; Pu Y; Yin L; Liang G
Oncol Rep; 2017 Jun; 37(6):3543-3553. PubMed ID: 28498428
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-663 suppresses cell invasion and migration by targeting transforming growth factor beta 1 in papillary thyroid carcinoma.
Wang Z; Zhang H; Zhang P; Dong W; He L
Tumour Biol; 2016 Jun; 37(6):7633-44. PubMed ID: 26687649
[TBL] [Abstract][Full Text] [Related]
26. MicroRNA-96 plays an oncogenic role by targeting FOXO1 and regulating AKT/FOXO1/Bim pathway in papillary thyroid carcinoma cells.
Song HM; Luo Y; Li DF; Wei CK; Hua KY; Song JL; Xu H; Maskey N; Fang L
Int J Clin Exp Pathol; 2015; 8(9):9889-900. PubMed ID: 26617698
[TBL] [Abstract][Full Text] [Related]
27. MicroRNA expression profile helps to distinguish benign nodules from papillary thyroid carcinomas starting from cells of fine-needle aspiration.
Agretti P; Ferrarini E; Rago T; Candelieri A; De Marco G; Dimida A; Niccolai F; Molinaro A; Di Coscio G; Pinchera A; Vitti P; Tonacchera M
Eur J Endocrinol; 2012 Sep; 167(3):393-400. PubMed ID: 22728346
[TBL] [Abstract][Full Text] [Related]
28. BCL2 and hsa-miR-181a-5p are potential biomarkers associated with papillary thyroid cancer based on bioinformatics analysis.
Zhang C; Bo C; Guo L; Yu P; Miao S; Gu X
World J Surg Oncol; 2019 Dec; 17(1):221. PubMed ID: 31842912
[TBL] [Abstract][Full Text] [Related]
29. Altered Serum MicroRNA Profile May Serve as an Auxiliary Tool for Discriminating Aggressive Thyroid Carcinoma from Nonaggressive Thyroid Cancer and Benign Thyroid Nodules.
Zhang A; Wang C; Lu H; Chen X; Ba Y; Zhang C; Zhang CY
Dis Markers; 2019; 2019():3717683. PubMed ID: 31636734
[TBL] [Abstract][Full Text] [Related]
30. Variants in microRNA genes in familial papillary thyroid carcinoma.
Tomsic J; Fultz R; Liyanarachchi S; Genutis LK; Wang Y; Li W; Volinia S; Jazdzewski K; He H; Wakely PE; Senter L; de la Chapelle A
Oncotarget; 2017 Jan; 8(4):6475-6482. PubMed ID: 28031538
[TBL] [Abstract][Full Text] [Related]
31. Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma.
Yu S; Liu Y; Wang J; Guo Z; Zhang Q; Yu F; Zhang Y; Huang K; Li Y; Song E; Zheng XL; Xiao H
J Clin Endocrinol Metab; 2012 Jun; 97(6):2084-92. PubMed ID: 22472564
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of plasma exosomal miRNAs as potential diagnostic biomarkers of lymph node metastasis in papillary thyroid carcinoma.
Chen W; Li G; Li Z; Zhu J; Wei T; Lei J
Endocrine; 2022 Mar; 75(3):846-855. PubMed ID: 34854020
[TBL] [Abstract][Full Text] [Related]
33. New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.
Saiselet M; Gacquer D; Spinette A; Craciun L; Decaussin-Petrucci M; Andry G; Detours V; Maenhaut C
BMC Genomics; 2015 Oct; 16():828. PubMed ID: 26487287
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic significance of elevated expression of HBME-1 in papillary thyroid carcinoma.
Chen YJ; Zhao RM; Zhao Q; Li BY; Ma QY; Li X; Chen X
Tumour Biol; 2016 Jul; 37(7):8715-20. PubMed ID: 26738867
[TBL] [Abstract][Full Text] [Related]
35. Selection and validation of miRNAs as normalizers for profiling expression of microRNAs isolated from thyroid fine needle aspiration smears.
Titov SE; Demenkov PS; Ivanov MK; Malakhina ES; Poloz TL; Tsivlikova EV; Ganzha MS; Shevchenko SP; Gulyaeva LF; Kolesnikov NN
Oncol Rep; 2016 Nov; 36(5):2501-2510. PubMed ID: 27666315
[TBL] [Abstract][Full Text] [Related]
36. miR-182 targets CHL1 and controls tumor growth and invasion in papillary thyroid carcinoma.
Zhu H; Fang J; Zhang J; Zhao Z; Liu L; Wang J; Xi Q; Gu M
Biochem Biophys Res Commun; 2014 Jul; 450(1):857-62. PubMed ID: 24971532
[TBL] [Abstract][Full Text] [Related]
37. Altered expression of DLG1-AS1 distinguished papillary thyroid carcinoma from benign thyroid nodules.
He T; Wang H; Sun J; Wu J; Gong F; Li S; Wang H; Li Y
BMC Endocr Disord; 2019 Nov; 19(1):122. PubMed ID: 31718630
[TBL] [Abstract][Full Text] [Related]
38. Plasma-Derived miRNA-222 as a Candidate Marker for Papillary Thyroid Cancer.
Kondrotienė A; Daukša A; Pamedytytė D; Kazokaitė M; Žvirblienė A; Daukšienė D; Simanavičienė V; Klimaitė R; Golubickaitė I; Stakaitis R; Šarauskas V; Verkauskienė R; Žilaitienė B
Int J Mol Sci; 2020 Sep; 21(17):. PubMed ID: 32899424
[TBL] [Abstract][Full Text] [Related]
39. Metabolomics of papillary thyroid carcinoma tissues: potential biomarkers for diagnosis and promising targets for therapy.
Shang X; Zhong X; Tian X
Tumour Biol; 2016 Aug; 37(8):11163-75. PubMed ID: 26935059
[TBL] [Abstract][Full Text] [Related]
40. Downregulation of miR‑486‑5p in papillary thyroid carcinoma tissue: A study based on microarray and miRNA sequencing.
Wen DY; Pan DH; Lin P; Mo QY; Wei YP; Luo YH; Chen G; He Y; Chen JQ; Yang H
Mol Med Rep; 2018 Sep; 18(3):2631-2642. PubMed ID: 30015845
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
